Intraoperative autologous blood donation preserves red cell mass but does not decrease postoperative bleeding.
BACKGROUND
Postoperative bleeding and transfusion remain a source of morbidity and cost after open heart operations. The benefit of the acute removal and reinfusion of fresh autologous blood around the time of cardiopulmonary bypass-a technique known as intraoperative autologous donation (IAD)-has not been universally accepted. We sought to more clearly evaluate the effects of IAD on allogeneic transfusion and postoperative bleeding by removing, preserving, and reinfusing a calculated maximum volume of fresh autologous whole blood.


METHODS
Ninety patients undergoing coronary artery bypass grafting or valvular operations were prospectively randomized to either have (IAD group) or not have (control group) calculated maximum volume IAD performed. Treatment was otherwise identical. Transfusion guidelines were uniformly applied to all patients.


RESULTS
An average volume of 1,540 +/- 302 mL of fresh autologous blood was removed and reinfused in the IAD group. Postoperative hematocrits were significantly greater at 12 and 24 hours postoperatively in the IAD group versus the control group despite a significant decrease in both the percentage of patients in whom allogeneic red blood cells were transfused (17% versus 52%; p < 0.01) and the number of red blood cell units transfused per patient per group (0.28 +/- 0.66 and 1.14 +/- 1.19 units; p < 0.01). Conversely, chest tube output, incidence of excessive postoperative bleeding, postoperative prothrombin time, and platelet and coagulation factor transfusion requirement did not differ between groups.


CONCLUSIONS
These results indicate that intraoperative autologous donation serves to preserve red blood cell mass. Its routine use in eligible patients is therefore justified. However, the removal and reinfusion of an individually calculated maximum volume of fresh autologous blood had no effect on postoperative bleeding or platelet and coagulation factor transfusion requirement. This lack of hemostatic effect belies the beliefs of many about the primary action of IAD, helps to delineate the optimal way in which to perform IAD, and carries implications regarding the use of allogeneic platelet and coagulation factors for the treatment of early postoperative bleeding.
Helm
R E
RE
Department of Cardiothoracic Surgery, New York Hospital-Cornell Medical Center, New York, USA.
Klemperer
J D
JD
Rosengart
T K
TK
Gold
J P
JP
Peterson
P
P
DeBois
W
W
Altorki
N K
NK
Lang
S
S
Thomas
S
S
Isom
O W
OW
Krieger
K H
KH
D000328:Adult; D001804:Blood Transfusion, Autologous; D001810:Blood Volume; D001026:Coronary Artery Bypass / Q000009:adverse effects; D004911:Erythrocyte Volume; D006350:Heart Valve Prosthesis / Q000009:adverse effects; D006400:Hematocrit; D006801:Humans; D015994:Incidence; D007430:Intraoperative Care; D019106:Postoperative Hemorrhage / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D011446:Prospective Studies; D013997:Time Factors